Host Immune Response Mechanisms Against Herpes Simplex Virus Type 2 Infection

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Herpes simplex virus type 2 (HSV-2) is a major cause of genital herpes, posing physical, psychological, and public health risks, including increased HIV susceptibility and neonatal transmission.
• HSV-2 establishes lifelong latent infections, and current interventions cannot eradicate the virus or prevent primary infection due to incomplete understanding of protective immunity and pathogenesis.
• Developing effective vaccines and therapeutics is hindered by the complex interplay between host immune responses and viral immune evasion strategies.

Purpose of the Study:

• To review and integrate current research on the innate and adaptive immune mechanisms involved in HSV-2 infection.
• To elucidate the dynamic host-virus interactions that dictate the course of HSV-2 infection and latency.
• To provide a theoretical foundation for the rational development of novel preventive vaccines and therapeutic agents against HSV-2.

Main Methods:

• Literature review and synthesis of current research findings on HSV-2 immunology and pathogenesis.
• Analysis of the roles of innate immune components, including mucosal barriers, TLRs, cGAS-STING, interferons, NK cells, and dendritic cells.
• Examination of adaptive immune responses, focusing on humoral immunity (antibodies) and cellular immunity (CD4+ T cells, tissue-resident memory T cells).

Main Results:

• The innate immune system provides the initial defense against HSV-2 through various mechanisms, but the virus employs immune modulatory proteins to evade these responses.
• Adaptive immunity, particularly cellular immunity mediated by CD4+ T cells and tissue-resident memory T cells, is crucial for viral clearance and controlling latent HSV-2 reactivation.
• While antibodies offer some mucosal protection, their efficacy is limited by viral immune evasion, highlighting the central role of cellular immunity.

Conclusions:

• A comprehensive understanding of the intricate balance between host immunity and HSV-2 immune evasion is essential for therapeutic and vaccine development.
• Targeting specific innate and adaptive immune pathways, particularly cellular immunity and memory T cell responses, holds promise for controlling HSV-2.
• Further research into host-virus molecular interactions is critical for designing effective strategies to combat HSV-2 infection and latency.